Scientific Titan Robert Langer: Pioneering the Optimal Path for Medical-Engineering Integration and Innovation Translation
From May 5 to 7, 2023, the 7th Future Healthcare Top 100 Conference was co-hosted by VB100, VCBeat, and Eggshell Research Institute, with Shanghai Zhangjiang Group as a strategic partner. Themed “Beyond East and West,” the conference brought together outstanding global medical and health innovation projects, scientific research achievements, strategic announcements from listed companies, and industry benchmarks for innovation. It outlined an era-specific landscape illustrating the close connection and positive interaction between China’s medical and health research and the development of its healthcare system, recorded the historical strides of China’s medical and health innovation, and showcased the confident, determined, and forward-moving spirit of China’s medical and health sector, undeterred by geographical or cultural boundaries.
Robert Langer, Institute Professor at the David H. Koch Institute for Integrative Cancer Research at MIT, has confirmed his attendance at the 7th Future Healthcare 100 Conference to discuss global medical innovation, translation, and development.
The "Edison" of the Pharmaceutical Industry—Robert Langer
Robert Langer
Professor, MIT David H. Koch Institute
Robert Langer is a professor, scientist, entrepreneur, and inventor.
In the scientific community, he conducts cutting-edge research in fields such as drug delivery systems, biomaterials, nanotechnology, tissue engineering, and regenerative medicine, earning him the reputation of being the “Edison” of the pharmaceutical industry. His primary research focuses on targeted drug delivery systems and tissue engineering, and he is hailed as the “Father of Tissue Engineering and Drug Delivery.”
In the industry, he founded Flagship VentureLabs, a venture capital firm dedicated to incubating small biotechnology companies. It has successfully incubated more than 40 companies, including Moderna, one of the global “Big Three” mRNA vaccine manufacturers; Sigilon Therapeutics, an emerging company in encapsulated cell therapy; and Immunai, an immunotherapy-focused biotechnology company.
Langer and the Translation of Medical Innovations
"Clinically oriented medical innovation translation and integration of medicine and engineering are gradually becoming a consensus, with innovative elements such as government, industry, academia, research, and capital forming synergy, ushering in a new era."
Interdisciplinary integration serves as the intrinsic driving force for scientific innovation and development. The vigorous advancement of modern medicine is closely linked to progress in disciplines such as biology, information technology, and chemistry, as well as related technological advancements.From initially relying on experience and experimentation to the comprehensive application of modern technologies such as digital imaging, big data, surgical robots, remote surgery, and computer-aided diagnosis and treatment, technology has become the primary driver propelling the development of the medical and health industry.
As the largest research group in the international field of tissue engineering, the Robert Langer Group operates the largest laboratory in the United States. With a staff of over 100 members and annual R&D funding exceeding $10 million, it is the world’s largest biomedical engineering laboratory. The group has been vigorously advancing along the path of integrated industry-academia-research collaboration for many years, achieving exceptionally high efficiency in both research and development and output.
Meanwhile, Professor Robert Langer is also known as “the most commercially successful scientist.” He has participated in the founding of more than 40 biotechnology companies, including Moderna, which successfully developed the first mRNA vaccine. To date, these ventures have raised a cumulative total of over $2 billion in funding. Initially, Professor Langer set out with the goal of discovering and creating technologies and inventions, publishing the results in academic papers, and hoping that industry would recognize their value and take them forward for commercialization. However, this idealistic vision did not materialize, prompting him to change strategy and establish his own companies. Since then, he has remained relentlessly active without pause. His entrepreneurial spirit and unique approach to technology transfer have become an industry benchmark and a widely celebrated story. He believes that launching science and technology innovation companies requires several key conditions, which he refers to as the “3Ps”: platform technology, published papers, and patents.
China’s medical innovation paradigm is shifting from “imitation-based” to “clinical demand-driven and medicine-engineering integrated.” To promote the integrated development and innovation of the Faculty of Medicine in the interdisciplinary field of medicine and engineering, explore optimal pathways for the translation of medical innovations, and jointly help medical innovation outcomes bridge the “valley of death” from 0 to 1, this conference has specially invited Professor Robert Langer from the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) to share his insights.
The 7th Future Healthcare Top 100 Conference
Conference Name:The 7th Future Healthcare Top 100 Conference
Conference Time:May 5–7, 2023
Conference Venue:China · Shanghai Zhangjiang Science Hall
Conference Format:Offline Summit
Conference Scale:Estimated 7,000 patient visits
Organizer:VB100, VCBeat, Eggshell Research Institute
Strategic Partner: Shanghai Zhangjiang Group
